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Abstract
Background: Peanut allergy is characterized by increased levels of peanut-specific IgE in the serum of most
patients. Thus, the most logical therapy would be to inhibit the IgE production by committed B-cells. This study
aims to investigate the unreported anti-IgE effects of Chinese herbal extracts of Rubia cordifolia (Qiancao) and
Dianthus superbus (Qumai).
Methods: Seventy herbal extracts were tested for their ability to reduce IgE secretion by a human B-cell line. Those
with the lowest inhibitory concentration 50 (IC50) values were tested in a mouse model of peanut-anaphylaxis.
Anaphylactic scores, body temperature, plasma histamine and peanut-specific-immunoglobulins were determined.
Results: Rubia cordifolia and Dianthus superbus inhibited the in vitro IgE production by a human B-cell line in a
dose-dependent manner and the in vivo IgE production in a murine model of peanut allergy without affecting
peanut-specific-IgG1 levels. After challenge, all mice in the sham groups developed anaphylactic reactions and
increased plasma histamine levels. The extract-treated mice demonstrated significantly reduced peanut-triggered
anaphylactic reactions and plasma histamine levels.
Conclusion: The extracts of Rubia cordifolia and Dianthus superbus inhibited the IgE production in vivo and in vitro
as well as reduced anaphylactic reactions in peanut-allergic mice, suggesting potentials for allergy treatments.
Background
Peanut allergy (PNA) is a worldwide health concern,
particularly in developed countries. PNA accounts for
approximately 80% of fatal and near-fatal food allergic
reactions [1]. The prevalence of childhood PNA in the
United States (USA) is currently at 1.4%, up from 0.8%
in 2002 and 0.4% in 1997 [1]. Apart from strict avoid-
ance of the peanut-containing foods, no satisfactory
therapy is available to prevent or reverse this condition.
Standard subcutaneous immunotherapy has been aban-
doned due to undesirable adverse reactions and mar-
ginal efficacy [2]. While peanut oral immunotherapy
(OIT) is a promising therapeutic intervention for PNA
[3], many questions remain, such as the risks of OIT
compared with avoidance, dosing regimen issues, patient
selection and post desensitization strategy [4].
Sublingual immunotherapy (SLIT) is a new method of
treating food allergy, with few systemic reactions; how-
ever, only one study [5] determined the effect of SLIT
on PNA. For these reasons, a safe and effective therapy
for peanut allergy is urgently needed.
Research suggests that certain Chinese medicinal
herbs may have the potential for treating allergy and
asthma [6]. For the first time, our group developed a
food allergy herbal formula (FAHF2) that blocks peanut-
induced anaphylaxis in a mouse model [7,8]. A recent
clinical trial demonstrated that the FAHF2 is safe and
well-tolerated, with beneficial immunomodulatory
effects in vitro [9].
Similar to other allergies, PNA is characterized by
increased levels of peanut-specific IgE in the serum of
most patients. Cross-linking of mast cell/basophil mem-
brane cell-bound IgE antibodies by allergen results in
the release of inflammatory mediators responsible for
the signs and symptoms of PNA [10]. Omalizumab
(Xolair) is the only available anti-IgE therapy which is
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effectively neutralizes IgE and may even cause apoptosis
of committed B-cells by cross linking membrane IgE.
However, relapse is likely if the antibody treatment
stops [11,12]. While investigation of anti-allergic thera-
pies from natural products sources has been increasing
in the past years, the number of studies on reducing IgE
production are limited [13].
T h ep r e s e n ts t u d ya i m st oi n v e s t i g a t eC h i n e s em e d i c -
inal herbs that have previously unreported anti-IgE
effects. Seventy herbal extracts were tested for their abil-
ity to reduce the IgE secretion by a human myeloma B-
cell line. Those with the lowest IC50 values were then
tested in a mouse model of peanut-anaphylaxis.
Methods
Herbs
All medicinal herbs used in this study were purchased from
EFong Herbs Inc. (USA). These products were made by
Gangdong Yifang Pharmaceutical Company Ltd. (China)
and commercially available in the US via EFong Herbs Inc.
All herbs were extracted with water and then concentrated
and dried. The manufacturing processes and the product
quality analyses are in accordance with GMP standards
[14]. Each powdered extract was packaged and stored at
room temperature under dark and dry conditions.
High performance liquid chromatography (HPLC)
fingerprints from Qiancao and Qumai
HPLC fingerprints are recommended by the United States
Food and Drug Administration as a means of standardiza-
tion for botanical products. HPLC was carried out as pre-
viously described [9,15,16]. Briefly, 200 mg of Qiancao
(QC) and Qumai (QM) extracts were dissolved into 2 mL
mobile phase mixture consisting of 0.10% formic acid and
acetonitrile (1:1). Each sample solution was filtered through
a0 . 2μm filter (Whatman Inc., USA). Each sample (10 mL)
was analyzed on a Waters Alliance 2695 HPLC system
(Waters Corporation, USA) with a photodiode array detec-
tor (2996) (Waters Corporation, USA). The separation con-
ditions were as follows: Zorbax SB-C18 column (150 × 4.6
mm; 5 μm particle size) from Agilent Technologies (USA);
mobile phases: 0.10% formic acid (A) and acetonitrile (B);
flow rate: 1.0 mL/min; detection wavelength: 254 nm. Lin-
ear separation gradient was from 2% of B to 48% for 75
minutes. Chromatographic results were acquired and pro-
cessed with the Waters’ Empower software (Waters Cor-
poration, USA). All chemicals and solvents used were of
HPLC grade (Fisher Scientific, USA). HPLC fingerprints of
QC and QM are shown in Figure 1.
U266 human B cell cultures and IgE measurement
Human U266B1 multiple myeloma cells (ATCC TIB-
196™, American Type Culture Collection, USA) were
cultured at 37°C in 5% CO2. RPMI 1640 medium, sup-
plemented with 10% of fetal bovine serum (FBS), 1 mM
sodium pyruvate, 1 × 10
-5 M 2-ME and 0.5% penicillin-
streptomycin, was used as a culture medium. Cells were
grown at an initial concentration of 2 × 10
5 cells/mL.
Initially, all herbal extracts (Table 1) were added at Day
0 at 500 μg/mL and 100 μg/mL. At Day 6 the superna-
tants were harvested for total IgE assay. For those herbs
with an IgE inhibition rate higher than 95% at both con-
centrations assayed, a dose-inhibition curve was
performed.
Total IgE (T-IgE) was examined with a fluorescent
enzyme immunoassay (ImmunoCAP FEIA, Phadia, Ger-
many) and expressed in kU/L. The detection range of
T-IgE was 2-2000 kU/L. Samples were measured undi-
luted, while samples with undetectable T-IgE were
assigned an arbitrary value of 1 kU/L. The percentage of
IgE inhibition was calculated as 100-[IgE concentration
(sample treated) × 100/IgE concentration (sample
untreated)]
Cell viability assays for QC and QM cultures
The viability of control and treated cells was evaluated
with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide (MTT) assay in triplicates. Briefly, cells
(2 × 10
4) were incubated in 96-well microtiter plate
containing 100 μL of the culture medium (RPMI 1640
medium supplemented with 10% FBS, 1 mM sodium
pyruvate, 1 × 10
-5 M 2-ME and 0.5% penicillin-strepto-
mycin) with or without tested compounds at 0, 3.125,
6.25, 12.5 25, 50, and 100 μg/ml). The MTT assay was
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Figure 1 HPLC chromatograms of Qiancao (Rubia cordifolia)
and Qumai (Dianthus superbus). Panel A: Qiancao; Panel B: Qumai.
HPLC conditions: column, Agilent Zorbax SB-C18 column (150 × 4.6
mm i.d.); flow rate, 1 mL/min; wavelength, 254 nm; mobile phase A,
0.1% formic acid, mobile phase B, acetonitrile. Data was analyzed
using Waters Empower software.
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Page 2 of 10Table 1 Selected Chinese medicinal plants with the percentage of IgE inhibition at the concentrations indicated
Pinyin name Botanical name Part used % IgE inhibition
500 μg/mL
% IgE inhibition
100 μg/mL
Ai Ye Artemisiae argyi Leaves 69.5 14.4
Bai Guo Ren Ginkgo bilobae Seeds 0 0
Bai He Lilium brownii Bulb 0 0
Bai Hua She She Cao Heydyotis diffusa Whole 19.4 10.8
Bai Jiang Cao Patrinia scabiosaefolia Whole 17.2 0
Bai Shao Paeoniae lactiflora Root 25.2 5.7
Bai Tou Weng Pulsatillae chinensis Root 86.5 11.5
Bai Zhu Atractylodes Macrocephala Rhizome 10.3 0
Ban Bian Lian Lobelia chinensis Whole 21.0 3.9
Ban Xia Pinellia ternata Rhizome 15.6 11.5
Ban Zhi Lian Scutellaria Barbata Whole 39.1 16.6
Bei Sha Shen Adenophora tetraphylla Root 7.0 0
Bu Gu Zhi Psoraleae coryfolia Fruit 17.4 21.4
Cang Er Cao Xanthium sibiricum Whole 7.2 11.5
Cang Zhu Atractylodes lancea Root 19.9 8.6
Chai Hu Bupleurum chinense Root 31.3 11.1
Chan Tui Cryptotympana atrata Seeds 1.0 0
Che Qian Zi Plantago asiatica Seeds 14.4 12.9
Chuan Xin Lian Melia toosedan Root 67.5 18.6
Da Huang Rheum palmatum Root 71.29 5.2
Da Qing Ye Isatis tinctoria Leaves 37.34 12.88
Dan Shen Salvia miltiorrhiza Root 81.09 3.1
Dang Gui Angelica sinensis Root 10.8 0
Di Gu Pi Lycium chinense Bark 31.35 0
E Jiao Equus asinus Gelatin 9.9 0
Fu Ling Poria cocos Fruit body 11.16 10.3
Gan Cao Glycyrrhiza uralensis Root 7.2 11.5
Gan Jiang Zingiber officinalis Root 15.4 2
Gua Lou Trichosanthes kirilowii Whole 44.7 22.6
Hong Hua Carthamus tinctorius Flower 0 10.3
Hong Shen Panax ginseng Root 19.9 4.3
Hou Po Magnolia officinalis Bark 90.1 64.0
Huang Bai Phellodendron amurense Bark 96.6 63.3
Huang Qin Scutellaria baicalensis Root 94.4 63.9
Huang Yao Zi Dioscorea bulbifera Seeds 70.9 15.0
Ku Shen Sophora flavescens Root 1.0 0
Ling Zhi Ganoderma Lucidum Fruit body 14.7 9.6
Ma Bo Lasiosphera fenslii Fruit body 4.5 ND
Mai Dong Ophiopogon japonicus Root 4.3 4.3
Mu Dan Pi Paeonia suffruticosa Root bark 95.7 14.3
Mu Gua Chaenomeles lagenaria Fruit 10.8 1.6
Mu Li Ostrea gigas Shell 9.1 5.2
Qian Cao Rubia cordifolia Root 98.7 98.5
Qu Mai Dianthus superbus Whole 98.4 96.7
Rou Gui Cinnamomum cassia Bark 13.3 0
San Qi Panax notoginseng Root 0 0
Shan Ci Gu Cremastra variabilis Fruit body 6.2 5.4
Shan Dou Gen Sophora tonkineenis Root 15.1 0
Shan Zha Crataegus pinnatifida Fruit 0 0
Shan Zhu Yu Cornus officinalis Fruit 16.1 8.2
She Gan Belamcanda chinensis Rhizome 54.1 15.1
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Page 3 of 10performed after six days. Cells in each well were incu-
bated at 37°C in 20 μg of the MTT (1 mg/mL) for four
hours. After incubation, 150 μLo fD i m e t h y ls u l f o x i d e
(DMSO) was added to each well. Absorbance of the
mixture at 595 nm was determined with a microplate
ELISA reader. The results were derived from three inde-
pendent experiments.
In vivo experimental protocol
Female C3He/J mice (6 weeks old) were purchased from
Jackson Laboratory (USA). Standard guidelines for the
care and use of animals were followed [17]. To generate
a peanut allergy model, we sensitized the mice intraperi-
toneally (i.p.) each week with 200 μg of crude peanut
extract (CPE) and 2 mg of alum in 0.5 mL of phosphate
buffered saline (PBS) for four weeks, and then chal-
lenged (i.p.) them with 1000 μg CPE in 500 μL PBS two
weeks after the last sensitization. To determine whether
QC and/or QM prevent peanut anaphylactic reactions,
we administered extracts of QC (2 mg) or QM (2 mg),
o rQ C( 4m g )o rQ M( 4m g )i n0 . 5m Lo fw a t e ri n t r a -
gastrically (i.g.) twice daily for five weeks beginning at
Day 0 of the protocol. The dose was determined by a
conversion table of equivalent human to animal dose
ratios based on body surface area [18]. Additional pea-
nut-sensitized mice received 0.5 mL water (i.g.) twice
daily for five weeks as sham treatment controls (sham).
Naïve mice served as normal controls (Figure 2).
Table 1 Selected Chinese medicinal plants with the percentage of IgE inhibition at the concentrations indicated
(Continued)
Sheng Jiang Drynaria fortunei Rhizome 90.6 14.2
Sheng Ma Cimicifuga foetida Rhizome/root 31.1 ND
Shi Chang Pu Acorus gramineus Rhizome 12.3 8.0
Si Gua Luo Luffa cylindrical Loofah 0 ND
Tian Dong Asparagus cochinchinensis Root 3.49 ND
Tian Hua Fen Trichosanthis kirilowii Root 12.78 ND
Tian Nan Xing Arisaema consaguineum Fruit 0 ND
Tou Weng Radix Pulsatibae Root 86.9 15.4
Tu Fu Ling Smilax glabra Rhizome 66.4 0
Wu Zhu Yu Evodia rutaecarpa Fruit 69.5 13.3
Xia Ku Cao Prunella vulgaris Flower 87.7 14.6
Xian He Cao Agrimonia pilosa Whole 71.7 0
Xiao Hui Xiang Foeniculum vulgare Whole 6.0 0
Yi Yi Renn Coix lachrymal jobi Seed 0 ND
Yu Mi Xu Zae mays Corn stigma 16.44 ND
Zhi Zi Gardenia jasminoides Seed 0 0
Zhu Ling Polysporus umbellatus Fruit body 8.14 ND
Zi Su Ye Perilla frutescens Flower 92.7 22.3
All Chinese herbal extracts listed were tested on the human B cell line (U266 B1) at 100 and 500 μg/ml. The pinyin and botanical names of the herbs tested in
this study are based on Chinese Herbal Medicine: Materia Medica [32] and the Pharmacopoeia of the People’s Republic of China [21].
0  7  14  35  Day 
CPE + Alum i.p.         Challenge 
Treatment d0-d34 
21 
Figure 2 Experimental protocol. Mice were sensitized weekly for four weeks intraperitoneally (i.p.) with 200 μg of CPE and 2 mg of alum and
then challenged i.p with 1000 μg CPE 2 weeks after the last sensitization. To determine whether QC and/or QM extracts prevent peanut
anaphylactic reactions, we administered QC or QM at 2 mg or 4 mg intragastrically (i.g.) to a group of mice twice daily for five weeks beginning
at Day 0 of the protocol (n = 5-8 mice per group).
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Page 4 of 10Assessment of systemic anaphylactic signs and
measurement of core body temperatures
Anaphylactic signs were evaluated 30 to 40 minutes
after the commencement of the challenge by two inves-
tigators using the following scoring: 0, no signs; 1,
scratching and rubbing around the mouth and head; 2,
puffiness and redness around the eyes and mouth, diar-
rhea, pilar erecti, reduced activity and/or decreased
activity with increased respiratory rate; 3, wheezing,
labored respiration and cyanosis around the mouth and
tail; 4, no activity after prodding or tremor and convul-
sions and 5, death. Rectal temperatures were measured
with a thermal probe (Harvard Apparatus, USA) every
15 minutes during the 30 minutes after the peanut
challenge.
Measurement of plasma histamine and mouse mast cell
protease-1 (MMCP1) levels
Plasma was obtained 30 minutes after the challenge, his-
tamine and MMCP1 levels were analyzed with an
enzyme immunoassay kit as described by the manufac-
turers (Immunotech, France and Moredun Scientific,
UK for histamine and MMCP1 measurements
respectively).
Measurement of serum antibodies
Retro-orbital venous blood was collected before the
challenge. Sera were collected and stored at -80°C until
analysis. Peanut-specific IgE and IgG1 levels were deter-
mined with a monoclonal antibody as previously
described [19].
Acute and sub chronic toxicity studies
T h el e t h a ld o s e5 0( L D 50) protocol was designed as fol-
lows. Seven-week old mice were fed 12 times the highest
therapeutic dose used in this experiment and observed
for 12 and 24 hours; the LD50 was then calculated. Mice
fed with water served as controls (sham). If no death
occurred 12 and 24 hours after feeding, mice were
observed for an additional 14 days. If no death occurred
during this observation period, all mice were sacrificed.
Samples were then collected for biochemical analyses,
complete blood cell counts (CBC) and histological ana-
lyses. Biochemical analyses of blood urea nitrogen
(BUN) as well as creatinine and alanine aminotransfer-
ase (ALT) were performed on a PROCHEM-V instru-
mentation (Synbiotics, USA) for the assessment of the
kidney and liver functions respectively. For CBC testing,
blood samples (20 μL) were collected and subjected to
analysis by Multispecies Hematology Systems (CDC
Technologies, USA). These assays were performed at
Mount Sinai School of Medicine, Center for Laboratory
Animal Sciences, where these assays are routinely per-
formed to monitor the health of laboratory animals.
Histological analysis of major organs (ie kidney, liver,
heart, spleen, lung, stomach and intestine) was per-
formed in a blinded manner.
Statistical analysis
One-way or two-way ANOVA (analysis of variance) was
performed followed by a Bonferroni correction for all
pairwise comparisons if the data were approximately
normal. If the data were not normally distributed, differ-
ences among multiple groups were analyzed by a Krus-
kal-Wallis ANOVA on ranks and Bonferroni correction
was performed for all pairwise comparisons. P values of
< 0.05, based on two-tailed tests, are considered statisti-
cally significant. Outliers were discarded based on
Grubss test [20]. All statistical analyses were performed
with GraphPad Prism (GraphPad Software Inc., USA).
Results
Anti-IgE screening for the Chinese medicinal herbs
Seventy herbs extracts from our herbal repository with
demonstrated anti-inflammatory actions were screened
for potential anti-IgE properties via incubating them
with an IgE producing human B-cell line (U266B1).
Herbal extracts were added at Day 0 at concentrations
of 500 μg/mL and 100 μg/mL. After six days of incuba-
tion, IgE levels in the supernatants were measured.
Forty-nine of the 70 herbal extracts inhibited IgE pro-
d u c t i o nb yl e s st h a n5 0 %a t5 0 0μg/mL. Nine inhibited
between 50% and 80%, and 12 inhibited more than 80%
(Table 1). At 100 μg/mL, the extracts of Houpo (Magno-
lia officinalis; 64%), Huangbai (Phellodendron amurense;
63.3%), Huangqin (Scutellaria baicalensis,6 3 . 9 % ) ,Q C
(Rubia cordifolia; 98.5%) and QM (Dianthus superbus;
96.7%) inhibited more than 50%. Due to their remark-
able inhibitory effects at 100 μg/ml, QC and QM were
selected for further studies. First, dose response curves
were determined as shown in Figure 3A and 3B. Both
extracts, dose-dependently (3.125-100 μg/mL) inhibited
IgE production, with IC50 values being 3.06 μg/mL (QC)
and 12.33 μg/mL (QM). Furthermore, QC and QM did
not affect the viability of U266B1 cells (Figure 3C and
3D), demonstrating that QC and QM have potent anti-
IgE effect in a non-toxic manner.
QC and QM suppressed peanut-specific IgE synthesis in
an in vivo model of peanut-anaphylaxis
Since sensitization of mast cells with IgE is an essential
mechanism in the anaphylaxis cascade, we evaluated the
effect of QC and QM on peanut-specific IgE production
in an in vivo model of peanut-anaphylaxis (Figure 2)
and found that QC (4 mg) and QM (4 mg)-treated mice
showed reductions of 80.47% (P=0.027) and 92.34% (P
= 0.007) respectively in their peanut-specific IgE levels
compared with sham-treated mice one week before the
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Page 5 of 10time of challenge (Figure 4). Peanut-specific-IgG1 levels
were slightly reduced in the QC (4 mg) and QM (4 mg)
treatment group, but the difference was not statistically
s i g n i f i c a n ta tt h i st i m ep o i n t( 9 . 9 1×1 0
6ng/mL ±
720345 for sham vs 8.73 × 10
6ng/mL ± 425234 for QC
(4 mg) and sham vs 7.83 × 10
6ng/mL ± 200283 for QM
(4 mg).
QC and QM decreased peanut triggered anaphylactic
reactions in a mouse model
In order to investigate whether QC and QM can prevent
anaphylaxis in vivo, we used peanut as a model antigen
to test the effects of QC and QM on peanut-induced
anaphylactic reactions. A mouse model of peanut allergy
was established (Figure 2). After challenge at Day 35, all
sham-treated mice developed anaphylactic reactions
(median score 2, Figure 5A and 5B). By contrast, mice
treated daily with QC (4 mg) or QM (4 mg) exhibited
significantly reduced anaphylactic symptoms (median
score 0; P< 0.001; Figure 5A and 5B). At a dose of 2
mg, only QC treated mice exhibited reduced anaphylac-
tic reactions (median score 1; P = 0.020; Figure 5A).
QC and QM prevented decreases in body temperature
after peanut challenge
Core body temperature drops during systemic anaphy-
laxis. We used rectal temperature measurement at 30
minutes after challenge as an objective measurement of
anaphylaxis. As shown in Figure 6A and 6B, mean tem-
peratures of the sham-treated mice were significantly
lower than those of the naïve mice (35.77 ± 0.79°C vs
38.96 ± 0.28°C; P< 0.001). Similarly mean temperatures
in the QC- and QM-treated mice were significantly
higher than in the sham-treated mice, namely 37.39 ±
0.79°C for QC (4 mg) and 37.62 ± 1.22°C for QM (4
mg) (Figure 6A and 6B) (P =0 . 0 0 1 8f o rQ Ca n dP=
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Figure 3 Inhibitory effects of (a) QC and (b) QM on IgE production from U266 human B cells. Cells were grown at an initial concentration
of 2 × 10
5cells/mL. QC and QM extracts were added at the indicated concentrations. At Day 6 the supernatants were harvested for total IgE
assay. Cell viability after culturing U266 human cells with (c) QC or (d) QM was performed with MTT assay after six days of culture. Bars represent
means ± SD of three independent experiments. ***P< 0.001 vs untreated.
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Page 6 of 100.004 for QM). As the strongest activity was found at
the dose of 4 mg/day/mouse, the rest of the experiments
used this dose.
QC and QM prevented histamine release after peanut
challenge
Anaphylactic scores in this model are associated with
plasma histamine levels. We determined histamine levels
30 minutes after challenge. As shown in Figure 7A,
plasma histamine levels were markedly elevated in the
sham-treated mice compared with naïve mice (sham vs
naïve, mean, μM: 6.843 ± 0.3970 vs 0.954 ± 0.085; P
<0.001). By contrast, histamine levels in the QC- and
QM-treated mice were significantly lower than those in
the sham-treated mice (P< 0.001). Plasma
MMCP1concentrations were also measured as an addi-
tional marker of mast cell degranulation. We found a
significant decrease in MMCP1 levels in the mice trea-
ted with 4 mg of QM (sham vs QM, mean, ng/mL:
519.8 ± 212.3 vs 238.6 ± 224.5; P = 0.042); however, no
significant differences were found in the QC-treated
mice.
Safety of QC and QM
In a preliminary safety assessment, we performed LD50
testing. No mouse died within the 12 hours after they
were administered the effective mouse daily dose of QC
or QM (n = 10), nor did any of them die during the
subsequent two weeks.
To further assess safety, we collected blood samples
specimens from mice two weeks after they were fed and
subjected to biochemical analysis of BUN and ALT for
the assessment of liver and kidney functions respec-
tively. All results were within the normal range (Table
2). Moreover, histological examination of the major
organs did not reveal any abnormalities.
Discussion
After screening 70 herbs extracts with previously
reported anti-inflammatory properties, we found that
QC and QM extracts markedly inhibited IgE production
by a B-cell human cell line over a concentration range
of 100 μg/mL to 3.125 μg/mL. The inhibition was not
due to toxicity because proliferation assays showed no
effect, even at the highest concentrations used (Figure
3 Ca n dF i g u r e3 D ) .Q Cr o o ti sl i s t e di nt h eC h i n e s e
Pharmacopoeia for the treatment of arthritis, chronic
P=0.027
P=0.007
P<0.001
Figure 4 Effect of QC and QM treatment on IgE production in
vivo. Blood from each group of mice was collected one week
before challenge. Peanut-specific IgE was measured by antigen-
specific ELISA. Results are expressed as means ± SD of triplicates for
each group (pooled samples; n = 5-8) P values are calculated vs
sham.
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Figure 5 Effect of (a) QC and (b) QM treatment on peanut-induced anaphylactic symptoms. Anaphylactic scoring was done as described
in the methods section. Symbols indicate individual mice from two sets of experiments (n = 5-8). Bars are medians of scores. P values are
calculated vs sham.
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Page 7 of 10bronchitis, uterine hemorrhage and uteritis [21]. Recent
studies have shown that QC roots have antibacterial,
antioxidant and anti-inflammatory activities [22-24].
QM is an important Chinese medicinal herb used as a
diuretic and an anti-inflammatory agent for the treat-
ment of urinary infections, carbuncles and carcinomas
[21]. To our knowledge, we are the first to report the
anti-IgE properties of both herbs. Kim, Lee, Won, Park,
Chae, Kim & Baek; Kim, Kim & Park and Kim & Moon
reported the IgE inhibitory effect of some other herbs
such as Asiasari Radix, Poncirus trifloliata and Sieges-
beckia glabrescens using the same cell line as in our
experiments; however, the concentrations required for
the inhibitory effects were higher than those in our
experiments [25-27]. Sugahara, Nishimoto, Morioka,
Nakano & Nakano [28] identified anti-IgE activity of
extracts of Sorghum bicolor (L.) Moench. In their experi-
ments, the extracts suppressed IgE production by the
human myeloma cell line U266 in a dose-dependent
manner but did not affect the IgG production by mice
splenocytes in vitro. We demonstrated a similar effect in
our in vivo studies, in which mouse serum peanut-speci-
fic IgG1 levels did not significantly differ between the
groups, suggesting that the effects of QM and QC are
IgE specific.
PNA accounts for approximately 80% of the fatal and
near-fatal anaphylactic reactions to foods [29]. As pea-
nut-induced anaphylaxis is IgE-mediated, we tested the
effects of QC and QM in a well established mouse
model of PNA. Mice in these experiments exhibited less
severe symptoms than in a previous study [8] perhaps
because mice in these studies were i.p. sensitized with
crude peanut extract whereas we used i.g. feeding of
ground whole peanut and chol e r at o x i ni no u rp r e v i o u s
studies. Mice’s sensitivity to antigen may also differ over
time. Recent studies [30,31] showed that longer sensiti-
zation protocols were required to produce the same
anaphylactic responses as in a previous study [8].
Both QC and QM prevented peanut-induced anaphy-
laxis. This protection could be a direct consequence of
the reduced peanut IgE levels induced by the QC and
QM treatment. Furthermore, significantly less histamine
release was observed in the treated animals. The
decrease may be attributed to reduced IgE production
by B-cells, leading to decreased availability of IgE for
participation in mast cell activation and consequently
mast cell degranulation upon antigen challenge. In this
model the severity of anaphylactic symptoms is corre-
lated with mast cell histamine release. Both QM and
QC significantly reduced plasma histamine levels follow-
ing peanut challenge of PNA mice, thereby protecting
against systemic anaphylaxis. Histamine release is a cen-
tral mechanism involved in the IgE-mediated type I
hypersensitivity reactions in humans and also an
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Figure 6 Effect of (a) QC and (b) QM treatment on core body
temperatures during challenge using a rectal thermometer.
Each data point indicates group means ± SD of individual mice
from two sets of experiments (n = 5-8).P values are calculated vs
sham.
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Figure 7 Effect of QC and QM treatment on histamine release
after challenge measured by ELISA. Plasma from each group of
mice was collected 30 minutes post-challenge. Results are expressed
as means ± SD of triplicates for each group (pooled samples; n =5 -
8). ***P< 0.001 vs sham.
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Page 8 of 10important parameter for evaluating the effects in this
model. Moreover, QM but not QC also produced signif-
icant suppression of MMCP1 release although both QM
and QC similarly suppressed systemic anaphylaxis, sug-
gesting that MMCP1may not be the most appropriate
marker of systemic anaphylaxis in this model.
Conclusion
Qiancao (Rubia cordifolia)a n dQumai (Dianthus
superbus) extracts inhibit the IgE production by plasma
cells in vitro and in mice in a non-toxic manner. This,
at least in part, may be responsible for the observed pro-
tection against anaphylaxis. Further research is war-
ranted to investigate the molecular mechanisms
underlying the inhibitory effects and to identify the
active compounds responsible for these effects. More
importantly, controlled clinical studies are required to
further ensure the safety and efficacy for the use of
these herbal products for human food allergy.
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